zolucatetide

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

News

Parabilis prices IPO at an ambitious $475 million

Parabilis has set the terms of its IPO, seeking to raise a hefty $475m for phase 3 trials of its lead drug for desmoid tumours.

News

Tuneable peptide biotech Parabilis files IPO

Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.

News

$100 bill with missing puzzle pieces to be inserted

Parabilis scores $305m in bumper biofinancing week

Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis prices IPO at an ambitious $475 million

Tuneable peptide biotech Parabilis files IPO

Parabilis scores $305m in bumper biofinancing week

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

zolucatetide

Editor's Picks